Program
empagliflozin
Also written as “BI 10773”, “Empagliflozin” and “BI10773”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Heart Failure · Diabetes Mellitus, Type 1 · Renal Insufficiency, Chronic · Diabetes Mellitus, Lipoatrophic, led by 15 companies.
Drug pageEmpagliflozin: every studyMany companies study it; this page follows only the 124 they lead. All 404 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 992 open or running | phase 4since Oct 27, 2015 | Nov 14, 2007 | Dec 11, 2026phase 1 · NCT07845630 |
| ADIUMits history only | 40 open or running | no phasesince Mar 9, 2026 | Mar 9, 2026 | none ahead |
| Getz Pharmaits history only | 41 open or running | phase 4since Nov 27, 2020 | Nov 27, 2020 | Dec 31, 2026phase 4 · NCT05164263 |
| Gedeon Richter Plc.its history only | 30 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 21 open or running | phase 4since Jan 15, 2026 | Aug 1, 2016 | Aug 2027phase 4 · NCT07365358 |
| Dong Wha Pharmaceuticalits history only | 20 open or running | phase 1since Apr 10, 2023 | Apr 10, 2023 | none ahead |
| Kobe Universityits history only | 20 open or running | phase 3since Jul 10, 2019 | Jul 10, 2019 | none ahead |
| Celltrionits history only | 11 open or running | phase 3since Jun 30, 2025 | Jun 30, 2025 | Dec 2026phase 3 · NCT07093476 |
| Dong-A STits history only | 10 open or running | phase 1since Dec 5, 2018 | Dec 5, 2018 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 16, 2021 | Nov 16, 2021 | none ahead |
| hyundai-pharmits history only | 11 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 3since Feb 9, 2017 | Feb 9, 2017 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| pharma-nuevaits history only | 11 open or running | phase 1since Mar 6, 2024 | Mar 6, 2024 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 4since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Oct 27, 2014.
- Dec 10, 2024Gedeon Richter Plc.’s first study: phase 1 study in Diabetes Mellitus, Type 2New to Gedeon Richter Plc.Gedeon Richter Plc. · NCT06766500 · 64 enrolled · Russian Federation
- Jan 20, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06792968 · 64 enrolled · Russian Federation
- Feb 7, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06823856 · 64 enrolled · Russian Federation
- Feb 19, 2025Nabiqasim Industries (Pvt)’s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan
- Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT06926660 · 492 enrolled · United States, Argentina, Australia and more
- Apr 30, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT06962826 · 14 enrolled · Germany
- Jun 17, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT07035457 · 15 enrolled · Germany
- Jun 30, 2025Celltrion’s first study: phase 3 study in Diabetes Mellitus, Type 2New to CelltrionCelltrion · NCT07093476 · 171 planned · South Korea
- Aug 5, 2025Phase 3 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT07107945 · 135 enrolled · United States, Argentina, Australia and more
- Aug 19, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT07133399 · 32 enrolled · Germany
- Jan 15, 2026Phase 4 study in Diabetes Mellitus, Type 2Chong Kun Dang Pharmaceutical · NCT07365358 · 200 planned · South Korea
- Mar 9, 2026ADIUM’s first study: no phase study in BioequivalanceNew to ADIUMADIUM · NCT07479108 · 32 enrolled · Mexico
- Jun 3, 20263 no phase studies in Bioequivalence Study in Healthy SubjectsADIUM · NCT07633054, NCT07633041, NCT07633028
- Sep 23, 2026Phase 1 study in HealthyBoehringer Ingelheim · NCT07845630 · 36 planned · Germany
Ahead
- Dec 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 2Celltrion · NCT07093476
- Dec 11, 2026Primary completion: phase 1 study in HealthyBoehringer Ingelheim · NCT07845630
- Dec 31, 2026Primary completion: phase 4 study in Diabetes Mellitus, Type 2Getz Pharma · NCT05164263
- Apr 16, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT07107945
TargetBeta
“An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dapagliflozin | AstraZeneca | phase 4 | 133 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 25 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07845630Healthy · Germany | 1 | Recruiting | Boehringer Ingelheim | Dec 11, 2026 | 36 |
| NCT07633054Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Nov 24, 2025 | 42 |
| NCT07633041Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Apr 4, 2025 | 42 |
| NCT07633028Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Apr 8, 2025 | 42 |
| NCT07479108Bioequivalance · Mexico | – | Completed | ADIUM | Dec 11, 2024 | 32 |
| NCT07365358Diabetes Mellitus, Type 2 · South Korea | 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | Aug 2027 | 200 |
| NCT07133399Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Oct 22, 2025 | 32 |
| NCT07107945Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Boehringer Ingelheim | Apr 16, 2027 | 135 |
| NCT07093476Diabetes Mellitus, Type 2 · South Korea | 3 | Recruiting | Celltrion | Dec 2026 | 171 |
| NCT07035457Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Aug 7, 2025 | 15 |
| NCT06962826Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 26, 2025 | 14 |
| NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Boehringer Ingelheim | Aug 14, 2026 | 492 |
| NCT06862739Diabetes Mellitus · Pakistan | 4 | Recruiting | Nabiqasim Industries (Pvt) | Apr 30, 2026 | 800 |
| NCT06823856Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | May 21, 2025 | 64 |
| NCT06792968Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | Apr 6, 2025 | 64 |
| NCT06766500Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | Feb 28, 2025 | 64 |
| NCT06578676Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Recruiting | hyundai-pharm | Sep 2, 2024 | 56 |
| NCT06308679Healthy Vollunteer | 1 | Not yet recruiting | pharma-nueva | May 31, 2024 | 28 |
| NCT05823883DW6014 · Korea, Republic of | 1 | UNKNOWN | Dong Wha Pharmaceutical | Jul 2023 | 30 |
| NCT05823870Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Mar 6, 2023 | 32 |
| NCT05359432Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | Getz Pharma | Aug 10, 2021 | 120 |
| NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Boehringer Ingelheim | Jun 19, 2023 | 714 |
| NCT05164263Diabetes Mellitus, Type 2 · Afghanistan, Kenya, Nigeria and more | 4 | Recruiting | Getz Pharma | Dec 31, 2026 | 2,000 |
| NCT05132023Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Apr 2, 2019 | 26 |
| NCT05083949Healthy · Brazil | 1 | Completed | Boehringer Ingelheim | Aug 6, 2021 | 32 |
| NCT04976283Diabetes Mellitus, Type 2 · Pakistan | 4 | UNKNOWN | Getz Pharma | May 15, 2023 | 123 |
| NCT04665284Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | Getz Pharma | Sep 15, 2020 | 244 |
| NCT04531462Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Boehringer Ingelheim | Aug 19, 2022 | 129 |
| NCT04509674Myocardial Infarction · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Nov 5, 2023 | 6,522 |
| NCT04233801Diabetes Mellitus, Type 2 · China | 3 | Completed | Boehringer Ingelheim | Mar 3, 2022 | 219 |
| NCT04221152Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans · Japan | 3 | UNKNOWN | Kobe University | Feb 1, 2022 | 8 |
| NCT04157751Heart Failure · United States, Belgium, Canada and more | 3 | Completed | Boehringer Ingelheim | May 28, 2021 | 530 |
| NCT04018365Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans · Japan | 3 | UNKNOWN | Kobe University | Jul 31, 2021 | 8 |
| NCT03766724Type2 Diabetes · Korea, Republic of | 1 | Completed | Dong-A ST | Jan 18, 2019 | 42 |
| NCT03629054Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 5, 2018 | 30 |
| NCT03594110Renal Insufficiency, Chronic · United States, Canada, China and more | 3 | Completed | Boehringer Ingelheim | Jul 5, 2022 | 6,609 |
| NCT03448419Heart Failure · United States, Australia, Canada and more | 3 | Completed | Boehringer Ingelheim | Sep 30, 2019 | 312 |
| NCT03448406Heart Failure · United States, Australia, Canada and more | 3 | Completed | Boehringer Ingelheim | Oct 4, 2019 | 315 |
| NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Boehringer Ingelheim | Oct 19, 2022 | 175 |
| NCT03332212Heart Failure · United Kingdom | 3 | Completed | Boehringer Ingelheim | May 21, 2020 | 72 |
| NCT03259490Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 13, 2017 | 30 |
| NCT03254849Diabetes Mellitus, Type 2 · Germany | 4 | Completed | Profil Institut für Stoffwechselforschung | Apr 20, 2020 | 75 |
| NCT03057977Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | May 1, 2020 | 3,730 |
| NCT03057951Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Apr 26, 2021 | 5,988 |
| NCT03060980Diabetes Mellitus, Type 2 · United States, Canada | 3 | Terminated | Intarcia Therapeutics | Jan 26, 2018 | 245 |
| NCT02854748Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | Chong Kun Dang Pharmaceutical | Sep 2016 | 30 |
| NCT02821910Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Oct 1, 2016 | 50 |
| NCT02815644Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Oct 5, 2016 | 22 |
| NCT02782624Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 2009 | 16 |
| NCT02758171Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 29, 2016 | 56 |
| NCT02702011Diabetes Mellitus, Type 1 · Japan | 2 | Completed | Boehringer Ingelheim | Sep 5, 2016 | 48 |
| NCT02632747Diabetes Mellitus, Type 1 · Canada | 2 | Completed | Boehringer Ingelheim | Dec 19, 2017 | 31 |
| NCT02589639Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Boehringer Ingelheim | Apr 18, 2017 | 269 |
| NCT02589626Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Boehringer Ingelheim | Jun 2, 2017 | 65 |
| NCT02580591Diabetes Mellitus, Type 1 · United States, Australia, Canada and more | 3 | Completed | Boehringer Ingelheim | Sep 12, 2017 | 977 |
| NCT02577315Healthy · Russian Federation | 1 | Completed | Boehringer Ingelheim | Oct 2015 | 25 |
| NCT02489968Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Boehringer Ingelheim | Nov 18, 2016 | 880 |
| NCT02453555Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Boehringer Ingelheim | Aug 26, 2016 | 275 |
| NCT02414958Diabetes Mellitus, Type 1 · United States, Australia, Austria and more | 3 | Completed | Boehringer Ingelheim | Apr 20, 2017 | 730 |
| NCT02276365Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 20 |
How it is read
Names in the registry
- “BI 10773”, 71 entries
- “Empagliflozin”, 53 entries
- “BI10773”, 7 entries
- “Empagliflozin/Metformin”, 4 entries
- “Empagliflozin + Linagliptin”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 67 studies
- Heart Failure, 6 studies
- Diabetes Mellitus, Type 1, 5 studies
- Renal Insufficiency, Chronic, 4 studies
- Diabetes Mellitus, Lipoatrophic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.